ImmuPharma PLC

ImmuPharma PLC is a clinical-stage specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics to tackle autoimmune diseases and infectious diseases. Its primary mission centers on curing autoimmune conditions by addressing root causes through innovative precision therapies, rather than merely managing symptoms with biologics or small molecules. The lead program, P140 (Lupuzor or forigerimod), represents the world’s first immunormalizer, an autophagy immunomodulator designed to restore immune homeostasis for treating lupus and chronic inflammatory demyelinating polyneuropathy (CIDP), complemented by a next-generation companion diagnostic for precision patient identification. In anti-infectives, the pipeline features BioAMB, an improved peptide-based version of amphotericin-B with reduced side effects, and BioCin, an enhanced antibacterial for high-need resistant infections. Operating from London with a small team of around six employees, ImmuPharma PLC advances a differentiated pipeline protected by patents until 2045, positioning it as a pioneer in peptide therapies and precision immunology within the biotechnology sector.